BioNTech to SHUT Singapore mRNA Plant by 2027 as Sales Plummet
BioNTech is turning out the lights at the Singapore plant and planned regional headquarters it purchased from Novartis at the height of the COVID-19 outbreak, reflecting a sharp reversal in the mRNA specialist’s trajectory since the pandemic’s end. BioNTech announced the purchase of the Singapore facility from Novartis in November 2022, the same year the …